As Novartis AG and Gilead Sciences Inc. illustrated with recent approvals for Beovu (brolucizumab-dbll) and Descovy (emtricitabine and tenofovir alafenamide), sponsors taking advantage of the US Food and Drug Administration's priority review voucher incentive program have a high rate of on-time, first-cycle approvals.
Approval with a priority review voucher (PRV) occurs an average of 3.9 months earlier than for a new molecular entity...






